Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

European Research Council grant · Running

ONCO-SPLICE Translating Tudor domain splicing inhibitors for oncological applications

Coordinator
Cemm - Forschungszentrum Fuer Molekulare Medizin GmbH, Austria
Runs
1 September 2024 to 28 February 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101189441

What the project is doing

In the project's own words, from its summary on CORDIS.

In our effort to characterize metabolic activities in the cells nucleus, we discovered that the understudied Tudor domain protein SMNDC1 controls the repression of insulin in pancreatic alpha cells through its role as a splicing modulator. Based on this finding, we developed the first selective SMNDC1 Tudor domain inhibitors, for which we observe interesting preliminary data on insulin induction in primary human pancreatic islets.

However, as a pan-essential gene expressed in most tissues, SMNDC1 is not an ideal therapeutic target in diabetes, where exceptionally high safety margins are required. Interestingly, independent findings published in a preprint established a role for SMNDC1 in cancer. These data show that SMNDC1 controls splicing of the ERK1 exon that bears the phosphorylation signal mediating RAS/RAF/MEK/ERK signaling. A significant fraction of ovarian and pancreatic carcinomas harbor SMNDC1 amplifications, and cells derived from these tumors depend on SMNDC1 both in vitro and in xenograft models.

We here propose to evaluate the potential of our SMNDC1 inhibitors for cancer therapy. Experimentally, we will test these compounds in the ERK1 splicing dependent models in collaboration with the groups that described these findings, and we will profile their antiproliferative effects against a panel of >900 cancer cell lines. In parallel, we will conduct detailed analysis on the chemical scaffolds we discovered and develop a medicinal chemistry proposal to expand the scope of the filed patent application.

Additionally, we will commission analyses for an optimal translation pathway of these compounds to the clinic, aiming an ideal positioning for certain cancer subtypes based on market size, competitive situation, clinical needs and trial design opportunities. Finally, we will develop a plan for the further translation of our discoveries, ideally by foundation of a new spin-off company following successful completion of the ONCO-SPLICE project.

Topics

Who is involved

OrganisationCityCountryRole
Cemm - Forschungszentrum Fuer Molekulare Medizin GmbHWienAustriaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI